Press Room

Article / Oct 11, 2007

Speech by Guy Villax at the VPP Star Presentation

East Windsor, New Jersey, 11 October 2007

Speech by Guy Villax on the occasion of the presentation of VPP Star plaque and flag

Mr. Ambassador [Mr. Joao Salgueiro, Ambassador of the Republic of Portugal to the UN]
Mr. Roskoski, [Mr. Gary Roskoski, Director- Marlton Area Office. OSHA] 
Mayor Mironov, [Ms. Janice Mironov, Mayor of the Township of East Windsor] 
Mr. Consul General [Mr. Francisco Azevedo, Consul General of Portugal in Newark]
Ladies and Gentlemen,
Dear Friends

I am very glad to be here with you.

I would like to thank the kind words from Mr. Gary Roskoski, Director and Mr. Martin Davies both of OSHA, from Mayor Mironov.

This is an important event for Hovione's Technology Transfer Center – we celebrate OSHA’s acceptance of our application to the VPP Star program.

This acknowledgement of an impeccable HSE record is something that I see as a reflection of the TTC’s standards, of the quality of the management of this site, and in a way this marks the coming of age of the TTC. Indeed this site is only 5 years old – and this is the first time that we have the chance to stop, invite our guests and friends and take a moment to look back. It’s not been easy, but we’ve clearly moved to the next step.

We have established the TTC as a member of an elite group – in the words of Edwin J. Foulke, Assistant Secretary of Labour – not just in HSE terms, but as a service provider of sophisticated R&D services to the pharma industry.

This is the correct moment to say a few words of thanks.

First to the East Windsor Township, its Mayor and Council – because they helped us decide to locate here, they welcomed us and told us “we’ll be as fast as you want provided you do it by the book!”.

Then to CUH2A, our architects that turned a dream, Dave, Bill and I had into reality – or at least into a blueprint – many sushi lunches at figuring out how to make it the best.

Turner and to Dion Hall of Eng Tech – for the hardware.

Millennium BCP bank – supported us all the way, and together with BES, BPI and CGD financed this investment.

The Consulate in Newark for endless stampings of endless papers.

The universities – Rider, Rutgers and Princeton – that lend us a hand only too often, train our young people so they will lead us in the future.

The Twin Rivers association – our neighbours… to whom we have tried very hard to be the opposite of a nuisance.

Certainly our customers – because at the end of the day they are the reason why we exist and succeed – I will pick a few names – Neurocrine Biosciences – because they gave us our first business here; and CVT and Astellas because they bet on us for an important new product.

I’d like to also thank all the Hovione people for their efforts and commitment in turning what back in 1999 and 2000 was but a dream – into a tangible reality that clients and competitors talk about, and journalists write about! Journalists have played an important role in our success - this is something we appreciate very much.

All Hovione sites perform over and above the regulations, and all get awards and commendations – they work hard to be a welcome part of their communities; they are often picked as an example to follow. So when I saw the letter from OSHA in Washington I was particularly pleased, because it came as a surprise – I did not even know the TTC had made the application – and it shows that whether they be in China or in America – Hovione people have the same culture, and look to meet the toughest challenges, to meet the highest standards – not because it is mandatory, but because this is just the way we work.

To achieve this means great team spirit, because Safety is everyone’s job – so cohesion and alignment are part of the whole process. This occasion is also a happy one because it marks an achievement, Diane and I are here, to share it with you – and to tell you how pleased we are to see after 50 years of hard work how we are able to get recognition for a job well done everywhere we go – and how this is the result of people that come from nearby, and from Macau, and from Portugal.

Going forward we have a great challenge – to continue to meet the standard. We all want to retain the VPP Star status – but to keep it requires effort and commitment – one day of lost work will cause us to loose the status… so we need to work hard because from where OSHA has put us, we can only go down… so I count on you.

Lastly I would like to give my congratulations to Dave that has led this project from its beginning and who should feel that all this is the achievement of a team he led, coached, pushed forward and got amazing results from. Congratulations to all of you for a great job well done – congratulations also to everyone else that worked here at the TTC, and may not be here to hear these words. Thank you – well done.

Guy Villax 
Chief Executive 
East Windsor, 11th October 2007

Also in the Press Room

See All

The latest from CDMOs, CMOs, and suppliers featuring Thermo Fisher Scientific, Lonza, SK pharmteco/Lotte Biologics, Hovione, Sai Life Sciences, BioCina, Alcami, Piramal Pharma/IntoCell and Roquette. Formulation Development/Drug Product Manufacturing: Hovione Completes Initial $100-M Investment Cycle in US Operations Hovione, a CDMO of drug substances and drug products, has completed an initial $100-million investment cycle at its site in East Windsor, New Jersey, as part of a strategy to increase its US operations and enhance its integrated drug-substance, drug-product intermediate, and drug-product capabilities. Upon completion, the site will cover more than 200,000 square feet.   The initial expansion phase includes a 31,000-square-foot building that will house two size-3 spray dryers (PSD-3) designed for production of amorphous solid dispersions (ASDs). This investment more than doubles Hovione’s spray-drying capacity in the US by expanding capabilities for ASD development and commercial manufacturing. Construction is underway at the New Jersey site, with GMP operations planned to start in the second quarter of 2026.  As part of this expansion, Hovione has also acquired additional adjacent land to enable future growth at the East Windsor site. The 125,000-square-foot greenfield will support large-scale production, including continuous and batch tableting capacity, and introduce the latest pharmaceutical technologies and digital innovation with enhanced quality control and R&D capabilities.    Read the full article at DCATvci.org  

Press Clipping

Supplier News: Thermo Fisher, Lonza, SK pharmteco, Hovione & More

Oct 30, 2025

Today marks the start of CPhI Frankfurt, a huge trade show in Germany focused on the supply of pharmaceutical ingredients and other services to the drug industry. C&EN editor in chief Nick Perkins, life sciences editor Laura Howes, and reporter Aayushi Pratap are all there to meet drug outsourcing executives and take the pulse of the sector. In advance of CPhI, Cambrex and Wilmington PharmaTech both just announced big investments in US plants that make active pharmaceutical ingredients. And the Portuguese pharmaceutical services firm Hovione says it has completed a $100 million investment in New Jersey (story below). (...) Hovione invests in spray-drying in New Jersey The pharmaceutical services firm Hovione says it has spent $100 million to expand its operation in East Windsor, New Jersey. The facility spray-dries drug ingredients to create amorphous solid dispersions, which improve solubility and bioavailability. The Portuguese company says the new spray dryers will begin operating in the second quarter of 2026. The New Jersey facility opened in 2002, making Hovione one of the longest-established European pharmaceutical services firms in the US, CEO Jean-Luc Herbeaux says in a press release. Hovione says it has purchased land adjacent to the East Windsor site on which it can add new facilities for services such as spray-drying and drug tableting. Hovione is also investing at its sites in Ireland and Portugal. —Michael McCoy   Read the full article at CEN.acs.org  

Press Clipping

Oct. 28 Business Watch: More plants closing in Europe, Novartis to pay $12 billion for biotech firm

Oct 28, 2025

Developing drugs with poor water solubility remains a major challenge for pharmaceutical manufacturers, because solubility impacts bioavailability and effective drug delivery. The vast majority of small molecule drug candidates have low water solubility. For more than two decades, the most successful particle engineering technology to improve drug solubility and bioavailability has been spray drying with an amorphous solid dispersion (ASD) platform. Spray drying improves the solubility of oral drugs, inhalable particles, and excipients, and increases the stability of heat-sensitive drug products. Hovione, recognized globally for its industry-leading spray drying capabilities, has recently completed a $100 million investment cycle to enhance its operations in New Jersey. This initiative has successfully doubled Hovione’s spray-drying capacity in the US, strengthening its position in the industry. Hovione’s Expanded U.S. Site in East Windsor, NJ  The first phase of the expansion in East Windsor, NJ, delivers a new 31,000 square foot facility and houses two size-3 spray dryers (PSD-3). This additional capacity allows Hovione to meet increasing customer demand for ASD development and good manufacturing practice (GMP) commercial production. GMP operations are scheduled to commence in the second quarter of 2026.  Hovione has also acquired 15 acres of neighboring land, strategically positioning itself for future growth and evolving customer needs for U.S. manufacturing. The newly acquired greenfield site will provide future support for PSD-4–scale commercial production as well as continuous and batch tableting production. It will also be a hub for centralized logistics, enhanced quality control laboratories, and next-generation research and development facilities.  A Global CDMO with a Growing U.S. Footprint  Hovione has operated in New Jersey for more than two decades, establishing itself with a strong U.S. presence for the production of drug substances, intermediates, and finished drug products. A continued emphasis on an integrated service offering, including spray drying, supports delivering innovative medicines to patients more quickly.  The expansion of the East Windsor site addresses the rising demand for U.S. manufacturing and is an integral part of the company's ongoing global growth strategy, with facilities in Portugal, Ireland, and Macau. The company continues to bolster a cohesive network for drug development and commercial manufacturing unified by a corporate quality system and governance framework.  The integrated offering enhances development speed and eases technology transfers by unifying the team's technical skills, proprietary technologies, and digital platforms to efficiently produce drug substance to drug products at a single-site, through Hovione’s “one site, one partner” vision. Furthermore, Hovione’s strategic partnership model offers customers exclusive access to advanced technologies and resources while aiding in the optimization of their development programs and ensuring sustained value creation.  End-to-End Spray Drying and Particle Engineering: From Grams to Tons Hovione is a global leader in spray drying and particle engineering. Services include solubility enhancement and controlled-modified release via development and production of ASDs of both small and large molecules, supporting various modalities. ASD-HIPROS, Hovione’s proprietary spray drying screening platform, identifies optimal formulations that offer optimal performance and stability. By increasing production volume in the US, Hovione will meet customer demand for spray drying services:  Development services in the laboratory (1 g – 1 kg batches)  Pilot scale production (0.5 – 25 kg batches)  Small-scale production (5 – 200 kg batches)  Large-scale commercial manufacturing (50 – 400 kg batches) A Commitment to Sustainability  Hovione’s core values include a commitment to sustainability at all facilities. This commitment is reflected in a business strategy that focuses on improving the communities where the company operates. Hovione’s sustainability policy and strategy align with the UN Sustainable Development Goals and include adherence to science-based targets in line with the Paris Agreement to address climate change. Meeting these goals has required a dedication to process intensification and ensuring sustainability of manufacturing processes. This has been possible through strategic planning and commitments from senior management to ensure sustainability is addressed throughout the drug development life cycle.  Partner with a Technology-Leading CDMO for U.S. Manufacturing   As demand for poorly water-soluble drug formulations continues to rise in the U.S., expanding spray drying throughput is essential to meet the need for innovative therapeutics. With proven leadership in spray drying to manufacture ASDs, Hovione is able to support pharmaceutical companies by solving their solubility challenges efficiently and reliably.  Partnering with a CDMO that combines global leadership, advanced technologies, and the necessary manufacturing capacity in the U.S., drug developers can expedite time to market, ensure quality, and deliver innovative medicines to patients faster.  If your company is seeking access to the latest spray-drying capabilities, expanded U.S. manufacturing capacity, and an accelerated path to regulatory filing and commercialization, contact our team today.     

News

Hovione is Expanding Spray Drying Capacity for U.S. Drug Manufacturing

Oct 27, 2025